[{"orgOrder":0,"company":"Prasco Laboratories","sponsor":"Thea Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Prasco Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Prasco Laboratories \/ Th\u00e9a Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Prasco Laboratories \/ Th\u00e9a Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Prasco Laboratories

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Tafluprost Ophthalmic Solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

                          Product Name : Tafluprost-Generic

                          Product Type : HPAPI

                          Upfront Cash : Inapplicable

                          November 18, 2022

                          Lead Product(s) : Tafluprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Thea Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank